Skip to main content

Table 1 Correlation between ANLN expression and clinicopathological characteristics

From: ANLN is a prognostic biomarker independent of Ki-67 and essential for cell cycle progression in primary breast cancer

  Cohort I Cohort II
Characteristic Low ANLN NF n (%) High ANLN NF n (%) p-value Low ANLN NF n (%) High ANLN NF n (%) p-value
Age (years)
  ≤ median 42 (67.7) 20 (32.3)   138 (68.0) 65 (32.0)  
  > median 32 (50.0) 32 (50.0) 0.043 110 (71.0) 45 (29.0) 0.544
Tumor size (mm)
  ≤ 20 42 (72.4) 16 (27.6)   99 (76.7) 30 (23.3)  
  > 20 32 (47.1) 36 (52.9) 0.004 149 (65.1) 80 (34.9) 0.021
ER status
 Negative 6 (31.6) 13 (68.4)   50 (43.9) 64 (56.1)  
 Positive 68 (63.6) 39 (36.4) 0.009 191 (81.6) 43 (18.4) <0.001
PR status
 Negative 15 (39.5) 23 (60.5)   46 (40.7) 67 (59.3)  
 Positive 59 (67.0) 29 (33.0) 0.004 188 (82.5) 40 (17.5) <0.001
Grade (NHG)
 I 16 (100.0) 0 (0.0)   36 (97.3) 1 (2.7)  
 II 43 (74.1) 15 (25.9)   130 (86.7) 20 (13.3)  
 III 15 (28.8) 37 (71.2) <0.001 76 (47.2) 85 (52.8) <0.001
Nodal status
 Negative 41 (63.1) 24 (36.9)   64 (66.0) 33 (34.0)  
 Positive 25 (49.0) 26 (51.0) 0.129 183 (70.4) 77 (29.6) 0.423
Ki-67
  ≤ 10% 50 (96.2) 2 (3.8)   101 (91.8) 9 (8.2)  
  > 10% 22 (30.6) 50 (69.4) <0.001 142 (59.4) 97 (40.6) <0.001
HER2 status
 0–2+ 72 (61.5) 45 (38.5)   193 (70.4) 81 (29.6)  
 3+ 2 (22.2) 7 (77.8) 0.021 28 (58.3) 20 (41.7) 0.095
  1. ER estrogen receptor, PR progesterone receptor, NHG Nottingham histological grade, HER2 human epidermal growth factor receptor 2
  2. Age was defined as years at diagnosis. Positive ER and PR expression was considered as >10%. Chi square test, linear-by-linear test or Fisher’s exact test were used to test the significance between groups. Significant correlations (p < 0.05) are indicated by bold numbers